Giiant Pharma announced today that it added $1.25 million to its seed financing round to ensure reaching clinical proof-of-concept.
Montreal-based Giiant’s $750,000 in funding from AQC Capital, plus $500,000 from CQDM, adds to the seed round closed last month to bring the company’s total funding to nearly $15 million.
Get the full story at our sister site, Drug Delivery Business News.
A turgid month for the medtech industry might be drifting into the past after the past week indicated a slight turnaround as summer nears.
MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week at 107.74 points, marking a 1.4% rise from the 106.22-point mark set one week prior.
Having endured its largest slide of 2021 in recent weeks, the index is already demonstrating signs of a rebound after April brought the industry’s all-time best performance.
Despite the setbacks that have plagued the industry over the past month or so, medtech’s performance continues to reflect a rebound from the struggles brought on by the COVID-19 pandemic. Overall, it has registered a 16.7% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus a 73.4% increase from the mid-pandemic low of 62.13 (March 23, 2020).
The overall markets were on the opposite end of the spectrum over the p…
Giiant Pharma announced today that it closed a $11 million seed financing round for its drug delivery technology platform.
Montreal-based Giiant develops the Precision Delivery technology platform, which originated from the work from former Merck Frosst scientists, according to a news release. The company designs gut-restricted, tissue-specific, small molecule, drug therapeutics to be delivered through the platform.
Get the full story at our sister site, Drug Delivery Business News.